Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.

Journal of the Formosan Medical Association = Taiwan yi zhi

Volumn 107, Issue 12 Suppl, 2008, Pages 19-27

  Wang, Sue Jane ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIOASSAY; CLINICAL TRIAL; DRUG SCREENING; GENOMICS; HUMAN; METHODOLOGY; PATIENT SELECTION; PHARMACOGENETICS; STATISTICAL MODEL;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; ENDPOINT DETERMINATION; GENOMICS; HUMANS; MODELS, STATISTICAL; PATIENT SELECTION; PHARMACOGENETICS; RESEARCH DESIGN;

MLCS; MLOWN;

EID: 65449163762     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0929-6646(09)60005-x     Document Type: Article

References (0)